Opendata, web and dolomites

NeuroPa SIGNED

Targeting the brain sigma-1 receptor: A paradigm shift for the treatment of neuro-degenerative disorders

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NeuroPa project word cloud

Explore the words cloud of the NeuroPa project. It provides you a very rough idea of what is the project "NeuroPa" about.

drugs    total    orphan    neuropa    impressive    profile    close    peak    effect    societies    changing    competing    2018    full    comparably    slow    alzheimer    ad    addressable    investor    2b    amyotrophic    161    biggest    qualities    repositioning    aging    candidates    projected    asset    an    safety    multiple    strategy    excellent    sigmathera    french    muscle    regulator    pressing    lethality    tries    modifying    reflected    worldwide    spasms    patent    receptor    neurodegeneration    previously    prevalent    speaking    data    symptoms    treatments    provides    proof    progression    fail    sigma    positioning    feasibility    critical    market    abandoned    protection    drug    western    clinical    population    candidate    company    severity    disease    sit    commercial    patients    pipeline    neurodegenerative    efficacy    compound    original    brain    suffering    lateral    proven    treatment    regulatory    trials    paralysis    life    als    diseases    sales    sclerosis    urgent    trillion    euros    motor    depression    million    swallowing    humans    symptomatic   

Project "NeuroPa" data sheet

The following table provides information about the project.

Coordinator
SIGMATHERA SAS 

Organization address
address: AGROPOLIS 2, 2196 BOULEVARD DE LA LIRONDE
city: MONTFERRIER SUR LEZ
postcode: 34980
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SIGMATHERA SAS FR (MONTFERRIER SUR LEZ) coordinator 50˙000.00

Map

 Project objective

An increasingly aging population suffering from neurodegenerative diseases represents one of the biggest challenges for Western societies. Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease with over 50 million patients worldwide and an estimated cost of 1 trillion euros in 2018. In addition, orphan neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) have a comparably urgent need for treatment, because of the severity and life changing effect of the motor symptoms (muscle spasms, speaking and swallowing problems, full paralysis and lethality). As current treatments are only symptomatic and fail to slow down the disease progression, there is a pressing need for novel effective disease-modifying treatments.

SigmaThera is a French company that tries to address the need for effective treatments for neurodegenerative diseases by focusing on the repositioning of drug candidates: applying the proven qualities of previously developed drugs for new diseases. For our lead compound SIT-161 with an excellent safety profile in humans (the candidate was abandoned after original Phase 2 trials for major depression) we have obtained impressive proof-of-concept data and patent protection for the treatment of neurodegenerative diseases, including AD & ALS. The drug targets a brain sigma-1 receptor, a critical regulator of multiple processes in neurodegeneration and provides unique efficacy and safety compared to other competing candidates in the pipeline. The high commercial potential of the drug is reflected in the €6.2B total addressable market and projected peak sales of €2B. In the NeuroPa project, SigmaThera will investigate market positioning, clinical and regulatory feasibility, future patent strategy and investor strategy to bring this promising asset close to market implementation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUROPA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEUROPA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More